Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin and myocardial performance in type 2 diabetes with coronary artery disease
2009-012776-27Phase 4Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sitagliptin in type 2 diabetes mellitus (T2DM) and coronary arteriosclerosis, sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Effect of sitagliptin on left ventricular ejection fraction following dobutamine stress. Started Sep 2009; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)coronary arteriosclerosis
Beyond the preview
Go deeper on 2009-012776-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012776-27.